Jeffrey Humphrey

Dr. Jeffrey Humphrey is currently Chief Medical Officer (CMO) of Magenta Therapeutics in charge of clinical development of the company’s pipeline of drugs to improve mobilization of stem cells and conditioning for stem cell transplants. Dr. Humphrey was previously CMO of Constellation Pharmaceuticals, recently acquired by Morphosys, directing development of drugs that modify epigenetic regulation of gene expression. Previously at Kyowa Kirin as Chief Development Officer, he built the company’s US and EU clinical research capabilities and guided development of burosumab, mogamulizumab, and istradefylline to approvals and US/EU launches (Crysvita®, Poteligeo®, Nourianz®). Dr. Humphrey began industry clinical research at Bristol-Myers Squibb and subsequently served in management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol-Myers Squibb, participating in development of novel oncology drugs in all phases, from pre-IND to post-launch (Nexavar®, Erbitux®, Sprycel®, Yervoy®).

Dr. Humphrey is a graduate of Harvard College and Case Wester Reserve University School of Medicine, and completed medical residency at the Johns Hopkins Hospital and post-doctoral fellowships in human genetics and medical oncology at the National Cancer Institute, with board certification in oncology.